Non-Alcoholic Steatohepatitis Treatment Market 2026–2030: Forecast, Innovation, and Competitive Trends
Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis treatment market from 2026–2035 with trusted insights from The Business Research Company
How much is the Non-Alcoholic Steatohepatitis Treatment Market valued at in 2026, and what valuation is forecast for 2030?
The non-alcoholic steatohepatitis treatment market size has seen substantial growth in recent times. It is anticipated to expand from $3.57 billion in 2025 to $4.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 39.6%. The historical rise in this market can be attributed to the increasing prevalence of obesity, a growing incidence of type 2 diabetes, elevated consumption of processed foods, insufficient awareness about liver health, and the limited availability of treatment options for early-stage NASH.
The market for non-alcoholic steatohepatitis treatment is projected to experience rapid expansion over the coming years. This market is anticipated to reach a valuation of $18.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 39.7%. Factors contributing to this growth during the forecast timeframe include progress in precision medicine, the creation of new NASH medications, wider use of digital health monitoring instruments, government efforts to prevent liver disease, and greater financial commitment to liver disease studies. Key trends expected during this period encompass individualized lifestyle and diet strategies, breakthroughs in non-invasive diagnostics, campaigns raising awareness about fatty liver disease, at-home liver health surveillance, and the development of new pharmacological treatments.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
What Drivers Are Influencing The Growth Of The Non-Alcoholic Steatohepatitis Treatment Market?
The increasing occurrence of insulin resistance has been a significant driver for the non-alcoholic steatohepatitis treatment market’s future growth. Insulin resistance is a condition where muscle, fat, and liver cells fail to adequately respond to insulin, making it difficult for them to absorb glucose from the blood, thus leading to high blood sugar. This condition is frequently linked to an unhealthy lifestyle, excessive sugar consumption, and genetic factors. The incidence of insulin resistance has escalated due to the rising prevalence of diabetes and other liver-related issues, which often require non-alcoholic steatohepatitis treatment. For instance, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported notable increases in the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance. These rates rose from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Therefore, the heightened prevalence of insulin resistance, arising from numerous liver and diabetes diseases, is set to drive the non-alcoholic steatohepatitis treatment market.
What Segments Are Included Within The Non-Alcoholic Steatohepatitis Treatment Market?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Which Innovation Trends Are Advancing Developments Within The Non-Alcoholic Steatohepatitis Treatment Market?
Leading companies in the non-alcoholic steatohepatitis treatment market are actively developing innovative solutions, such as endogenous hormones, to reach wider customer bases, increase sales, and boost revenue. Endogenous hormones are naturally occurring substances produced within the body by various glands, tissues, or organs, playing vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin to individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is distinguished by its engineered glycoPEGylated analog of fibroblast growth factor 21. This specific formulation is currently being developed for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s unique aspect lies in its use of specialized glycoPEGylated technology, which ensures an extended half-life while preserving its potency. This advanced approach enhances the product’s effectiveness in modulating key factors related to lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.
Who Are The Top-Performing Companies In The Non-Alcoholic Steatohepatitis Treatment Market In Recent Years?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Access The Complete Report For Deeper Market Insights:
Which Region Currently Holds The Largest Share Of The Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Non-Alcoholic Steatohepatitis Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
